| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.005 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.078 | 0.006 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.076 | 0.01 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.03 |